Valuing QALYs in Relation to Equity Considerations Using a Discrete Choice Experiment
PharmacoEconomics , Volume 33 - Issue 12 p. 1289- 1300
Background: To judge whether an intervention offers value for money, the incremental costs per gained quality-adjusted life-year (QALY) need to be compared with some relevant threshold, which ideally reflects the monetary value of health gains. Literature suggests that this value may depend on the equity context in which health gains are produced, but the value of a QALY in relation to equity considerations has remained largely unexplored. Objective: The objective of this study was to estimate the social marginal willingness to pay (MWTP) for QALY gains in different equity subgroups, using a discrete choice experiment (DCE). Both severity of illness (operationalized as proportional shortfall) and fair innings (operationalized as age) were considered as grounds for differentiating the value of health gains. Methods: We obtained a sample of 1205 respondents, representative of the adult population of the Netherlands. The data was analysed using panel mixed multinomial logit (MMNL) and latent class models. Results: The panel MMNL models showed counterintuitive results, with more severe health states reducing the probability of receiving treatment. The latent class models revealed distinct preference patterns in the data. MWTP per QALY was sensitive to severity of disease among a substantial proportion of the public, but not to the age of care recipients. Conclusion: These findings emphasize the importance of accounting for preference heterogeneity among the public on value-laden issues such as prioritizing health care, both in research and decision making. This study emphasises the need to further explore the monetary value of a QALY in relation to equity considerations.
|Organisation||Erasmus School of Health Policy & Management (ESHPM)|
van de Wetering, L, van Exel, N.J.A, Bobinac, A, & Brouwer, W.B.F. (2015). Valuing QALYs in Relation to Equity Considerations Using a Discrete Choice Experiment. PharmacoEconomics, 33(12), 1289–1300. doi:10.1007/s40273-015-0311-x